1. Home
  2. SRG vs STIM Comparison

SRG vs STIM Comparison

Compare SRG & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seritage Growth Properties

SRG

Seritage Growth Properties

N/A

Current Price

$1.56

Market Cap

102.5M

Sector

Real Estate

ML Signal

N/A

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

N/A

Current Price

$2.02

Market Cap

120.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRG
STIM
Founded
2015
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.5M
120.4M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
SRG
STIM
Price
$1.56
$2.02
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
140.5K
★ 1.2M
Earning Date
11-20-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
53.90
★ 57.25
EPS
N/A
★ N/A
Revenue
$18,204,000.00
★ $52,776,000.00
Revenue This Year
N/A
$8.63
Revenue Next Year
N/A
$9.24
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 3.30
N/A
52 Week Low
$1.55
$0.80
52 Week High
$4.23
$3.44

Technical Indicators

Market Signals
Indicator
SRG
STIM
Relative Strength Index (RSI) 40.46 43.06
Support Level $1.57 $1.92
Resistance Level $1.71 $2.31
Average True Range (ATR) 0.08 0.26
MACD 0.01 0.01
Stochastic Oscillator 9.43 10.44

Price Performance

Historical Comparison
SRG
STIM

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.

About STIM Neuronetics Inc.

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

Share on Social Networks: